Saturday 17 October 2026
Export WHWK’s income statement to Excel — free account
Whitehawk Therapeutics, Inc.
WHWK Healthcare Biotechnology
Whitehawk Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.1 million, down 72.5% from fiscal 2024. In the quarter to June 2026, revenue grew 33.5%, EPS grew 73.7% and free cash flow grew 72.6%, each against the same quarter a year earlier.
2.89
0.15
−4.93%
Follow WHWK
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (44.98%) | (68.54%) | (21.82%) | (13.82%) |
+8 more TTM periods Free account |
|
| (42.60%) | (64.12%) | (18.63%) | (12.36%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(44.02%) | (101.15%) | (15.31%) | (10.06%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.84) | (1.56) | (1.58) | (1.39) | |
Free Cash Flow |
(69.35) | (107.78) | (97.98) | (95.99) | |
Capital Expenditures |
— | — | (0.55) | (0.74) | |
| Other line items | |||||
Cash ROIC |
(18.60%) | (45.05%) | (34.75%) | (30.02%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.87 | 0.93 | 4.73 | 6.10 | |
Depreciation/Fixed assets |
(2,246.00) | (935.00) | (482.67) | (188.50) | |
Capex/Depreciation |
0.00 | 0.00 | 0.38 | 0.98 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.84) | (1.56) | (1.57) | (1.38) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates